CERo Therapeutics Holdings (CERo Therapeutics Holdings) Total Payout Yield % : 0.00 (As of May. 26, 2024)

View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Total Payout Yield %?

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

CERo Therapeutics Holdings's current Total Payout Yield % is 0.00%.

CERo Therapeutics Holdings Total Payout Yield % Historical Data

The historical data trend for CERo Therapeutics Holdings's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Total Payout Yield % Chart

CERo Therapeutics Holdings Annual Data

Trend

Dec21

Dec22

Total Payout Yield %

CERo Therapeutics Holdings Semi-Annual Data
	Dec21	Dec22
Total Payout Yield %	-	-

Competitive Comparison of CERo Therapeutics Holdings's Total Payout Yield %

For the Biotechnology subindustry, CERo Therapeutics Holdings's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CERo Therapeutics Holdings's Total Payout Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CERo Therapeutics Holdings's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where CERo Therapeutics Holdings's Total Payout Yield % falls into.

CERo Therapeutics Holdings Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

CERo Therapeutics Holdings's Total Payout Yield % for the fiscal year that ended in Dec. 2022 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Market Cap
	=	- (0	+	0	+	0)	/	0
	=	N/A%

CERo Therapeutics Holdings's annualized Total Payout Yield % for the quarter that ended in Dec. 2022 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	*	Annualized Factor	/	Market Cap
	=	- (0	+	0	+	0)	*	1	/	0
	=	N/A%

CERo Therapeutics Holdings Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.

CERo Therapeutics Holdings Total Payout Yield % Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's Total Payout Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Total Payout Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080

Website

https://www.cero.bio

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines

From GuruFocus

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

By Business Wire • 03-07-2024